ALDH1A1 as A Drug Target for Doxorubicin (G216)

Target Name: ALDH1A1

NCBI ID: G216

ALDH1A1

ALDH1A1 as A Drug Target for Doxorubicin

ALDH1A1 (HEL-9) is a protein that is expressed in most tissues and is involved in the detoxification of a class of drugs called xenobiotics, such as pesticides and other harmful chemicals. It is a member of the Aldh1 family of proteins, which are known for their ability to transfer electrons from molecules to one another.

One of the unique features of ALDH1A1 is its ability to interact with certain drugs, such as the chemotherapy drug doxorubicin. doxorubicin is a chemotherapy drug that is commonly used to treat various types of cancer, including breast cancer and colorectal cancer. However, doxorubicin can be difficult to deliver to cancer cells, and is often associated with severe side effects, such as nausea and vomiting.

To address this challenge, researchers have studied the ALDH1A1 protein and have found that it can help doxorubicin to reach cancer cells more effectively. This has led to the hypothesis that ALDH1A1 may be a drug target (or biomarker) for doxorubicin.

To further explore the potential of ALDH1A1 as a drug target, researchers conducted experiments to see if they could inhibit the activity of ALDH1A1 and improve the delivery of doxorubicin to cancer cells. They found that ALDH1A1 plays a critical role in the detoxification of doxorubicin, and that inhibiting its activity can significantly reduce the amount of doxorubicin that is available to cancer cells.

In addition to its role in doxorubicin detoxification, ALDH1A1 has also been shown to be involved in the detoxification of other drugs that are commonly used to treat cancer, such as chemotherapy drugs, toxins, and environmental pollutants. This suggests that ALDH1A1 may be a useful biomarker for tracking the effectiveness of cancer treatments and for identifying potential drug targets.

Furthermore, ALDH1A1 is also a potential target for new drugs for cancer treatment. Researchers are currently working on developing new drugs that can inhibit the activity of ALDH1A1 and improve the delivery of doxorubicin to cancer cells. These drugs may have a wide range of applications, including the treatment of various types of cancer, as well as diseases caused by other types of toxins and environmental pollutants.

In conclusion, the study of ALDH1A1 (HEL-9) has significant implications for the development of new cancer treatments. By inhibiting the activity of this protein, researchers have identified a potential drug target for doxorubicin and other chemotherapy drugs, and have shown that ALDH1A1 may be a useful biomarker for tracking the effectiveness of cancer treatments. Further research is needed to fully understand the role of ALDH1A1 in cancer treatment and to develop new drugs that can effectively target this protein.

Protein Name: Aldehyde Dehydrogenase 1 Family Member A1

Functions: Cytosolic dehydrogenase that catalyzes the irreversible oxidation of a wide range of aldehydes to their corresponding carboxylic acid (PubMed:19296407, PubMed:12941160, PubMed:15623782, PubMed:17175089, PubMed:26373694, PubMed:25450233). Functions downstream of retinol dehydrogenases and catalyzes the oxidation of retinaldehyde into retinoic acid, the second step in the oxidation of retinol/vitamin A into retinoic acid (By similarity). This pathway is crucial to control the levels of retinol and retinoic acid, two important molecules which excess can be teratogenic and cytotoxic (By similarity). Also oxidizes aldehydes resulting from lipid peroxidation like (E)-4-hydroxynon-2-enal/HNE, malonaldehyde and hexanal that form protein adducts and are highly cytotoxic. By participating for instance to the clearance of (E)-4-hydroxynon-2-enal/HNE in the lens epithelium prevents the formation of HNE-protein adducts and lens opacification (PubMed:19296407, PubMed:12941160, PubMed:15623782). Functions also downstream of fructosamine-3-kinase in the fructosamine degradation pathway by catalyzing the oxidation of 3-deoxyglucosone, the carbohydrate product of fructosamine 3-phosphate decomposition, which is itself a potent glycating agent that may react with lysine and arginine side-chains of proteins (PubMed:17175089). Has also an aminobutyraldehyde dehydrogenase activity and is probably part of an alternative pathway for the biosynthesis of GABA/4-aminobutanoate in midbrain, thereby playing a role in GABAergic synaptic transmission (By similarity)

The "ALDH1A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ALDH1A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets